Acceder

Publicaciones - HEMATOLOGÍA Y ONCOLOGÍA MÉDICA CLÍNICO-EXPERIMENTAL

Cargando...
Martinez-Montesinos L, Rivera-Caravaca JM, Agewall S, Soler E, Lip GYH, Marin F, Roldan V. Polypharmacy and adverse events in atrial fibrillation: Main cause or reflection of multimorbidity? Biomed Pharmacother. 2023 Feb;158:114064. doi: 10.1016/j.biopha.2022.114064. Epub 2022 Dec 7. PubMed PMID: 36495662.
AÑO: 2023; IF: 7.5
36495662
Morales ML, Ferrer-Marin F. Deepening Our Understanding of the Factors Affecting Landscape of Myeloproliferative Neoplasms: What Do We Know about Them? Cancers (Basel). 2023 Feb 20;15(4):1348. doi: 10.3390/cancers15041348. PubMed PMID: 36831689; PubMed Central PMCID: PMC9954305.
AÑO: 2023; IF: 4.5
36831689
Jimenez-Fonseca P, Foy V, Raby S, Carmona-Bayonas A, Macia-Rivas L, Arrazubi V, Cacho Lavin D, Hernandez San Gil R, Custodio A, Cano JM, Fernandez Montes A, Mirallas O, Macias Declara I, Vidal Tocino R, Visa L, Limon ML, Pimentel P, Martinez Lago N, Sauri T, Martin Richard M, Mangas M, Gil Raga M, Calvo A, Reguera P, Granja M, Martin Carnicero A, Hernandez Perez C, Cerda P, Gomez Gonzalez L, Garcia Navalon F, Pacheco Barcia V, Gutierrez Abad D, Ruiz Martin M, Weaver J, Mansoor W, Gallego J. The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy. Ther Adv Med Oncol. 2023 Mar 4;15:17588359231157641. doi: 10.1177/17588359231157641. eCollection 2023. PubMed PMID: 36895850; PubMed Central PMCID: PMC9989382.
AÑO: 2023; IF: 4.3
36895850
Berna-Erro A, Ramesh G, Delgado E, Corbacho AJ, Ferrer-Marin F, Teruel R, Granados MP, Rosado JA, Redondo PC. CAPN1 (Calpain1)-Dependent Cleavage of STIM1 (Stromal Interaction Molecule 1) Results in an Enhanced SOCE (Store-Operated Calcium Entry) in Human Neonatal Platelets. Arterioscler Thromb Vasc Biol. 2023 May;43(5):e151-e170. doi: 10.1161/ATVBAHA.122.318015. Epub 2023 Mar 16. PubMed PMID: 36924231.
AÑO: 2023; IF: 7.4
36924231
Cabrera-Serrano AJ, Sanchez-Maldonado JM, Ter Horst R, Macauda A, Garcia-Martin P, Benavente Y, Landi S, Clay-Gilmour A, Niazi Y, Espinet B, Rodriguez-Sevilla JJ, Perez EM, Maffei R, Blanco G, Giaccherini M, Cerhan JR, Marasca R, Lopez-Nevot MA, Chen-Liang T, Thomsen H, Gamez I, Campa D, Moreno V, de Sanjose S, Marcos-Gragera R, Garcia-Alvarez M, Dierssen-Sotos T, Jerez A, Butrym A, Norman AD, Luppi M, Slager SL, Hemminki K, Li Y, Berndt SI, Casabonne D, Alcoceba M, Puiggros A, Netea MG, Forsti A, Canzian F, Sainz J. Do GWAS-Identified Risk Variants for Chronic Lymphocytic Leukemia Influence Overall Patient Survival and Disease Progression? Int J Mol Sci. 2023 Apr 28;24(9):8005. doi: 10.3390/ijms24098005. PubMed PMID: 37175717; PubMed Central PMCID: PMC10178669.
AÑO: 2023; IF: 4.9
37175717
< AnteriorSiguiente >
IMIB-Arrixaca

Instituto de Investigación Sanitaria Acreditado

ISCII

HEMATOLOGÍA Y ONCOLOGÍA MÉDICA CLÍNICO-EXPERIMENTAL